Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 Recruiting
80 enrolled
MetroWilms
Phase 1/2 Recruiting
28 enrolled
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Phase 1/2 Recruiting
15 enrolled
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Phase 1/2 Recruiting
22 enrolled
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/2 Recruiting
56 enrolled
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Phase 1/2 Recruiting
27 enrolled
64Cu-GRIP B in Patients With Advanced Malignancies
Phase 1/2 Recruiting
91 enrolled
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/2 Recruiting
64 enrolled
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/2 Recruiting
30 enrolled
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
TREAT-HF
Phase 1/2 Recruiting
53 enrolled
Panc 002
Phase 1/2 Recruiting
23 enrolled
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Phase 1/2 Recruiting
52 enrolled
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Phase 1/2 Recruiting
54 enrolled
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
120 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Phase 1/2 Recruiting
204 enrolled
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Phase 1/2 Recruiting
36 enrolled
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/2 Recruiting
96 enrolled
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Phase 1/2 Recruiting
70 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Phase 1/2 Recruiting
42 enrolled
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Phase 1/2 Recruiting
126 enrolled
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
Phase 1/2 Recruiting
30 enrolled
EMPOWER
Phase 1/2 Recruiting
65 enrolled
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Phase 1/2 Recruiting
70 enrolled
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1/2 Recruiting
27 enrolled
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Phase 1/2 Recruiting
24 enrolled
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Phase 1/2 Recruiting
54 enrolled
PROOV
Phase 1/2 Recruiting
55 enrolled
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2 Recruiting
54 enrolled
TumorGlow Intraoperative Molecular Imaging (IMI)
Phase 1/2 Recruiting
500 enrolled
DURABLE
Phase 1/2 Recruiting
56 enrolled
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase 1/2 Recruiting
40 enrolled
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
Phase 1/2 Recruiting
29 enrolled
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/2 Recruiting
15 enrolled
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1/2 Recruiting
31 enrolled
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Phase 1/2 Recruiting
49 enrolled
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
30 enrolled
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
116 enrolled
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Phase 1/2 Recruiting
24 enrolled
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Phase 1/2 Recruiting
55 enrolled
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Phase 1/2 Recruiting
48 enrolled
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Phase 1/2 Recruiting
29 enrolled
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Phase 1/2 Recruiting
77 enrolled
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Phase 1/2 Recruiting
98 enrolled
ADORATION
Phase 1/2 Recruiting
46 enrolled
Topical Imiquimod Treatment of Oral Dysplasia
Phase 1/2 Recruiting
20 enrolled
CAVALRY
Phase 1/2 Recruiting
104 enrolled
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
Phase 1/2 Recruiting
24 enrolled